Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Bernt Kartman"'
Publikováno v:
Value in Health. 20:357-371
Background Type 2 diabetes mellitus (T2DM) is chronic and progressive and the cost-effectiveness of new treatment interventions must be established over long time horizons. Given the limited durability of drugs, assumptions regarding downstream rescu
Autor:
Philip Christopher McEwan, H Bennett, Bernt Kartman, Christopher Edmonds, Ingrid Anna Gause-Nilsson
Publikováno v:
Diabetes. 68
Chronic kidney disease (CKD) and end stage renal disease (ESRD) pose a significant global health burden. Approximately 40% of people with type 2 diabetes develop CKD. The Dapagliflozin Effect on Cardiovascular Events (DECLARE)-TIMI 58 trial showed a
1213-P: Assessing the Performance of Cardiovascular Risk Equations in the DECLARE-TIMI 58 Population
Autor:
Christopher Edmonds, Volker Foos, Philip Christopher McEwan, H Bennett, Bernt Kartman, Ingrid Anna Gause-Nilsson
Publikováno v:
Diabetes. 68
Sodium-glucose co-transporter inhibitors have demonstrated reduced incidence of cardiovascular (CV) events, which cannot be fully explained by effects on HbA1c, body weight or blood pressure. Type 2 diabetes mellitus (T2DM) economic models link treat
Autor:
Ingrid Anna Gause-Nilsson, H Bennett, Bernt Kartman, Volker Foos, Philip Christopher McEwan, Christopher Edmonds
Publikováno v:
Diabetes. 68
Risk equations (RE) from the UK Prospective Diabetes Study (UKPDS) remain the most commonly used within economic models of type 2 diabetes mellitus (T2DM). However, clinical practice has evolved since UKPDS reported and the applicability of these RE
Publikováno v:
Journal of Medical Economics. 19:1127-1134
To assess the cost-effectiveness of exenatide 2 mg once-weekly (EQW) compared to dulaglutide 1.5 mg QW, liraglutide 1.2 mg and 1.8 mg once-daily (QD), and lixisenatide 20 μg QD for the treatment of adult patients with type 2 diabetes mellitus (T2DM)
Autor:
Susan Grandy, Heather Bennett, Greta Lozano-Ortega, Alka Shaunik, Bernt Kartman, Sheena Kayaniyil, Kristina Johnsson
Publikováno v:
Diabetes Therapy
Introduction Exenatide is a glucagon-like peptide-1 receptor agonist (GLP-1 RA), approved for treatment of type 2 diabetes mellitus (T2DM). There is limited direct evidence comparing the efficacy and tolerability of exenatide 2 mg once weekly (QW) to
Publikováno v:
Value in Health. 22:S581
Publikováno v:
F1000Research. 8:859
Background: Heart failure (HF) is increasing in prevalence worldwide. This systematic review was conducted to inform understanding of its humanistic and economic burden. Methods: Electronic databases (Embase, MEDLINE®, and Cochrane Library) were sea
Autor:
Peter Fenici, Thomas Ward, Bernt Kartman, C. Edmonds, H Bennett, P. McEwan, Marcus Thuresson, Mikhail Kosiborod
Publikováno v:
Value in Health. 21:S125
Publikováno v:
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research. 20(3)
Type 2 diabetes mellitus (T2DM) is chronic and progressive and the cost-effectiveness of new treatment interventions must be established over long time horizons. Given the limited durability of drugs, assumptions regarding downstream rescue medicatio